Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.49 |
| ▸ | VDR | P11473 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482082 | 0.92 | NR1H4 (0.51) | NR1H4VDRALOX5NLRP3CYP3A4 | |
| SCHEMBL1482606 | 0.92 | NR1H4 (0.49) | NR1H4VDRF10ALOX5CYP3A4 | |
| SCHEMBL1482376 | 0.87 | DRD2 (0.47) | NR1H4NLRP3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1482735 | 0.86 | NR1H4 (0.49) | NR1H4VDRALOX5DRD2TBXA2R | |
| SCHEMBL1482661 | 0.85 | NR1H4 (0.44) | NR1H4VDRF10ALOX5KCNH2 | |
| SCHEMBL1483014 | 0.84 | NR1H4 (0.51) | NR1H4VDRALOX5CYP3A4CYP2D6 | |
| SCHEMBL1482639 | 0.83 | NR1H4 (0.49) | NR1H4VDRALOX5CYP3A4CYP2D6 | |
| SCHEMBL1483074 | 0.81 | NR1H4 (0.49) | NR1H4VDRALOX5CYP3A4CYP2D6 | |
| SCHEMBL1481890 | 0.81 | NR1H4 (0.49) | NR1H4VDRALOX5CYP3A4CYP2D6 | |
| SCHEMBL1482662 | 0.81 | NR1H4 (0.51) | NR1H4VDRALOX5CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | NR1H4 776/4885VDR 1436/4885F10 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.